Tirzepatide
Also known as: Mounjaro · Zepbound · LY3298176
A dual GIP/GLP-1 receptor agonist delivering up to 22% weight loss in clinical trials. FDA-approved as Mounjaro and Zepbound, it outperforms single-pathway GLP-1 drugs.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
~5 days
10–15 mg weekly
Subcutaneous injection
Mechanism of Action
Simultaneously activates GIP and GLP-1 receptors to enhance insulin secretion, improve insulin sensitivity, reduce appetite, and promote fat oxidation.
Key Research Areas
Frequently Asked Questions
What is Tirzepatide?▾
How does Tirzepatide work?▾
What is the recommended dosage for Tirzepatide?▾
What is the half-life of Tirzepatide?▾
Is Tirzepatide FDA approved?▾
Ready to get started with Tirzepatide?
Order from our COA-verified partner — free US shipping, pharmaceutical-grade quality.
Research Disclaimer
The information provided about Tirzepatide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.